Earnings summaries and quarterly performance for ALUMIS.
Executive leadership at ALUMIS.
Martin Babler
Detailed
President and Chief Executive Officer
CEO
DG
David Goldstein
Detailed
Chief Scientific Officer
DR
Derrick Richardson
Detailed
Senior Vice President of People and Culture
JS
John Schroer
Detailed
Chief Financial Officer
JD
Jörn Drappa
Detailed
Chief Medical Officer
MB
Mark Bradley
Detailed
Chief Development Officer
RH
Roy Hardiman
Detailed
Chief Business and Strategy Officer
SP
Sanam Pangali
Detailed
Chief Legal Officer and Corporate Secretary
Board of directors at ALUMIS.
Research analysts covering ALUMIS.
Recent press releases and 8-K filings for ALMS.
Alumis Reports Positive Phase 3 Psoriasis Data for Envudeucitinib and Provides Updates on Regulatory Filings and SLE Trial
ALMS
Product Launch
New Projects/Investments
- Alumis announced positive top-line Phase 3 data for envudeucitinib in psoriasis in January, showing 74% average PASI 75 and 59% sPGA 0/1 at week 16, and 65% average PASI 90 and over 40% average PASI 100 at week 24, with a safety profile consistent with Phase 2.
- The company plans to submit the New Drug Application (NDA) for envudeucitinib in psoriasis in the second half of the year, following the receipt of 48-week data by mid-year.
- For commercialization of envudeucitinib, Alumis anticipates a partnership given the broad potential of the TYK2 franchise across multiple indications globally.
- A pivotal Phase 2b trial for envudeucitinib in Systemic Lupus Erythematosus (SLE), which has completed enrollment, is expected to read out data in the third quarter of this year.
2 days ago
Alumis Reports Positive Phase 3 Psoriasis Data and Upcoming SLE Trial Readout
ALMS
Product Launch
New Projects/Investments
- Alumis announced positive top-line Phase 3 data for envudeucitinib in psoriasis, achieving an average PASI 75 of 74% and sPGA 0/1 of 59% at week 16, with safety consistent with Phase 2.
- The company plans to submit its NDA for envudeucitinib in psoriasis in the second half of the year, following the availability of 48-week data by mid-year.
- A Phase 2b trial for envudeucitinib in Systemic Lupus Erythematosus (SLE), designed as a pivotal trial, completed enrollment last summer and is expected to read out data in the third quarter of this year.
- Alumis anticipates partnering for the global commercialization of envudeucitinib, especially considering its potential for up to 20 indications across the TYK2 franchise.
2 days ago
Alumis Discusses Positive Phase 3 Psoriasis Data and Future Milestones for Envudeucitinib
ALMS
Product Launch
New Projects/Investments
- Alumis announced positive top-line Phase 3 data for envudeucitinib in psoriasis, achieving an average PASI 75 of 74% and sPGA 0/1 of 59% at week 16, with a safety profile consistent with Phase II.
- The company plans to submit its New Drug Application (NDA) for envudeucitinib in psoriasis in the second half of 2026, following the availability of 48-week data by mid-2026.
- Data from the Phase 2b pivotal trial for envudeucitinib in Systemic Lupus Erythematosus (SLE) is expected to read out in the third quarter of 2026.
- Alumis intends to pursue a partnership for the commercialization of envudeucitinib, recognizing the broad potential of its TYK2 franchise.
- A once-a-day (QD) formulation for envudeucitinib is under development as a life cycle extension, but it will not be part of the initial launch.
2 days ago
Alumis Discusses Positive Psoriasis Phase 3 Data and Upcoming Milestones
ALMS
Guidance Update
New Projects/Investments
- Alumis reported strong Phase 3 results for its TYK2 inhibitor, envudeucitinib, in psoriasis, demonstrating significant PASI score reductions and a fast onset, with an abstract submitted for AAD.
- The company plans to file a New Drug Application (NDA) for envudeucitinib in psoriasis in the second half of 2026, pending durability and maintenance data from the ONWARD 3 study in Q2/early Q3 2026.
- Phase IIb results for the Systemic Lupus Erythematosus (SLE) program, designed as a pivotal study, are anticipated in Q3 2026.
- Alumis has a strong financial position with over $630 million in cash, providing a runway into the fourth quarter of 2027.
Feb 12, 2026, 2:00 PM
Alumis Provides Update on Psoriasis and Lupus Programs, and Financial Outlook
ALMS
Product Launch
New Projects/Investments
Guidance Update
- Alumis reported positive Phase III results for envudeucitinib in psoriasis, highlighting strong efficacy with PASI 75 in the 70s, PASI 90 at 65%, and PASI 100 over 40% at week 24, alongside a fast onset and consistent safety profile.
- The company expects to file a New Drug Application (NDA) for envudeucitinib in psoriasis in the second half of 2026, following the availability of withdrawal study data in Q2/early Q3 2026.
- Results from the pivotal Phase IIb study of envudeucitinib in Systemic Lupus Erythematosus (SLE) are anticipated in Q3 2026.
- Alumis has a strong financial position with just over $630 million in cash, providing a runway into the fourth quarter of 2027.
- While capable of independent market preparation, Alumis considers a partnership more likely for the global optimization of its TYK2 franchise across numerous potential indications.
Feb 12, 2026, 2:00 PM
Alumis Discusses Psoriasis Phase 3 Results, Upcoming Lupus Data, and Financial Runway
ALMS
New Projects/Investments
Guidance Update
- Alumis announced strong Phase 3 results for its peripheral TYK2 inhibitor, envudeucitinib, in psoriasis, reporting PASI 75 in the 70s, PASI 90 of about 65%, and PASI 100 over 40% at week 24, with a fast onset and consistent safety profile. The company expects to file an NDA in the second half of 2026, following the availability of durability and maintenance data from the ONWARD 3 study in Q2/early Q3 2026.
- The company anticipates Phase 2b results for its lupus (SLE) program in the third quarter of 2026; this study is designed as a pivotal trial with over 400 patients, aiming for a 15% improvement in BICLA for success. Alumis also intends to start a study for its brain-penetrant TYK2 in MS in the first half of 2026.
- Alumis has just over $630 million in cash, providing a runway into the fourth quarter of 2027. The company believes a partnership is more likely for global commercialization to optimize its TYK2 franchise across multiple indications, though launching alone is considered possible.
Feb 12, 2026, 2:00 PM
Alumis closes upsized public offering
ALMS
- Alumis Inc. announced the closing of its upsized underwritten public offering, which included the full exercise of the underwriters' option to purchase additional shares.
- The offering involved the sale of 20,297,500 shares of common stock at a price of $17.00 per share.
- This transaction generated approximately $345.1 million in gross proceeds for Alumis.
Jan 9, 2026, 9:05 PM
Alumis Inc. Announces Public Offering and Preliminary Cash Balance
ALMS
- Alumis Inc. entered into an underwriting agreement on January 7, 2026, for a public offering of 20,297,500 shares of its voting common stock, which includes 2,647,500 shares from a fully exercised option.
- The shares were offered at $17.00 per share, with the offering expected to close on January 9, 2026, generating approximately $345.1 million in gross proceeds for the company before deductions.
- As of December 31, 2025, the company reported preliminary unaudited cash, cash equivalents, and marketable securities of approximately $308.6 million.
Jan 9, 2026, 11:02 AM
Alumis Prices Upsized Public Offering of Common Stock
ALMS
- Alumis Inc. (Nasdaq: ALMS) announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock.
- The shares are priced at $17.00 per share, expected to generate approximately $300.0 million in gross proceeds for Alumis.
- All shares in the offering are being sold by Alumis.
- The offering is expected to close on January 9, 2026.
- Alumis has granted the underwriters a 30-day option to purchase up to an additional 2,647,500 shares of common stock.
Jan 8, 2026, 3:52 AM
Alumis Announces Proposed Public Offering of Common Stock
ALMS
- Alumis Inc. announced plans on January 6, 2026, to commence an underwritten public offering of $175.0 million of its common stock.
- The company expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares of its common stock.
- All shares in the proposed offering are being offered by Alumis.
- Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the offering.
Jan 6, 2026, 9:12 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more